Amgen Q1 2026: Revenue Grows 6% as Six Key Drivers Outpace Patent Losses

Amgen reported strong Q1 2026 results, with revenue up 6% to $8.6 billion and non-GAAP EPS up 5% to $5.15, exceeding expectations largely due to the performance of six key growth drivers. These drivers, including Repatha and the rare disease and oncology portfolios, significantly offset revenue losses from patent expirations. The company raised its full-year 2026 revenue and non-GAAP EPS guidance, indicating confidence in its growth trajectory despite some gross margin compression.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin